IL1B and respiratory tract infectious disorder: Relevant for the current review are previous observations suggesting a reduced risk for respiratory infections with the MeD [58] and especially a reduced risk of inflammation, with a decrease in C-reactive protein (CRP) and pro-inflammatory cytokines, such as interleukin (IL)-6 and IL-1β [59,60].